Related Experiment Videos
Evaluation of aztreonam in the treatment of severe bacterial infections
Abstract:
We investigated the clinical efficacy and safety of aztreonam in the treatment of 50 episodes of infection in 46 adult patients. The clinical condition of patients at the beginning of treatment was critical or poor in 28 of the episodes of infection. Episodes treated were 39 urinary tract infections (12 of them with concomitant bacteremia), 2 soft tissue infections, 8 patients with osteomyelitis (1 with concomitant bacteremia), and one episode of pneumonia. Significant isolated microorganisms were aerobic or facultative gram-negative rods and were responsible for the following episodes of infection (number of episodes): members of the family Enterobacteriaceae (49), Pseudomonas aeruginosa (5), and Haemophilus influenzae (1). The overall rate of clinical response to aztreonam was 94% of the treated episodes. Colonization or superinfection or both occurred in 29 episodes, but only 8 episodes required antimicrobial therapy. Aztreonam seems to be an effective single agent therapy for many bacterial infections. Colonization and superinfection by Candida sp., Streptococcus faecalis or Staphylococcus aureus must be monitored.
Insights
Aztreonam demonstrated high clinical efficacy (94%) in treating serious bacterial infections, including urinary tract infections and osteomyelitis. Careful monitoring for colonization and superinfection is recommended.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Aztreonam is a monobactam antibiotic with activity against aerobic gram-negative bacteria.
- Serious bacterial infections pose significant treatment challenges, particularly in critically ill patients.
Purpose of the Study:
- To evaluate the clinical efficacy and safety of aztreonam as a single agent therapy.
- To assess aztreonam's effectiveness in treating various infections caused by aerobic gram-negative rods.
Main Methods:
- Prospective investigation of aztreonam treatment in 46 adult patients with 50 infection episodes.
- Infections included urinary tract infections, soft tissue infections, osteomyelitis, and pneumonia.
- Microbiological analysis identified aerobic or facultative gram-negative rods, including Enterobacteriaceae, Pseudomonas aeruginosa, and Haemophilus influenzae.
Main Results:
- Overall clinical response rate to aztreonam was 94%.
- Effective in treating 39 urinary tract infections and 8 osteomyelitis cases.
- Colonization or superinfection occurred in 29 episodes, with 8 requiring further antimicrobial therapy.
Conclusions:
- Aztreonam is an effective single agent for treating numerous bacterial infections caused by aerobic gram-negative rods.
- Close monitoring for colonization and superinfection by Candida sp., Streptococcus faecalis, or Staphylococcus aureus is advised.